Breast Cancer最新文献

{"title":"Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database","authors":"Yuhang Shang, Xuelian Wang, Yansong Liu, Weilun Cheng, Yunqiang Duan, Zhengbo Fang, Jiangwei Liu, Fanjing Kong, Ting Wang, Tianshui Yu, Anbang Hu, Jiarui Zhang, Hanyu Zhang, Mingcui Li, Zhiyuan Rong, Yanling Li, Suborna S. Shakila, Xinxin Li, Jianyuan Feng, Fei Ma, Baoliang Guo","doi":"10.1007/s12282-024-01583-5","DOIUrl":"https://doi.org/10.1007/s12282-024-01583-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Guideline recommendations for the application of neoadjuvant chemotherapy (NACT) in T2N1M0 stage hormone receptor-positive, HER2-negative (HR + /HER2-) breast cancer are ambiguous. The debate continues regarding whether NACT or adjuvant chemotherapy (ACT) offers superior survival outcomes for these patients.</p><h3 data-test=\"abstract-sub-heading\">Materials and Methods</h3><p>Female patients diagnosed with HR + /HER2- breast cancer at T2N1M0 stage between 2010 and 2020, were identified from the Surveillance, Epidemiology, and End Results database and divided into two groups, the NACT group and the ACT group. Propensity score matching (PSM) was utilized to establish balanced cohorts between groups, considering baseline features. Kaplan–Meier (K-M) analysis and the Cox proportional hazards model were executed to assess the efficacy of both NACT and ACT in terms of overall survival (OS) and breast cancer-specific survival (BCSS). A logistic regression model was employed to examine the association between predictive variables and response to NACT.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>After PSM, 4,682 patients were finally included. K-M curves showed that patients receiving NACT exhibited significantly worse OS and BCSS when compared with patients undergoing ACT. Multivariable Cox analysis indicated that not achieving pathologic complete response (non-pCR) after NACT (versus ACT), was identified as an adverse prognostic factor for OS (HR 1.58, 95% CI 1.36–1.83) and BCSS (HR 1.70, 95% CI 1.44–2. 02). The logistic regression model revealed that low tumor grade independently predicted non-pCR.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Among T2N1M0 stage HR + /HER2- patients, OS and BCSS of NACT were inferior to ACT. Patients who attained non-pCR after NACT demonstrated significantly worse survival outcomes compared with those who received ACT.</p>","PeriodicalId":56083,"journal":{"name":"Breast Cancer","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140623810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study","authors":"Tetsuhiro Yoshinami, Shigenori E. Nagai, Masaya Hattori, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Hiroko Masuda, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori, Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwase, Miki Yamaguchi, Takafumi Sangai, Nobuyoshi Kosaka, Kentaro Tajima, Norikazu Masuda","doi":"10.1007/s12282-024-01575-5","DOIUrl":"https://doi.org/10.1007/s12282-024-01575-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>A recent large real-world study conducted in the United States reported the effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2− advanced breast cancer (ABC). However, local clinical practice and available medical treatment can vary between Japan and Western countries. Thus, it is important to investigate Japanese real-world data. This observational, multicenter study (NCT05399329) reports the interim analysis of effectiveness of palbociclib plus ET as first-line or second-line treatment for HR+/HER2− ABC by estimating real-world progression-free survival (rwPFS) and overall survival (OS) in Japanese routine clinical practice.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Real-world clinical outcomes and treatment patterns of palbociclib plus ET were captured using a medical record review of patients diagnosed with HR+/HER2− ABC who had received palbociclib plus ET in the first-line or second-line treatment across 20 sites in Japan. The primary endpoint was rwPFS; secondary endpoints were OS, real-world overall response rate, real-world clinical benefit rate, and chemotherapy-free survival.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Of the 677 eligible patients, 420 and 257 patients, respectively, had received palbociclib with ET as first-line and second-line treatments. Median rwPFS (95% confidence interval) was 24.5 months (19.9–29.4) for first-line and 14.5 months (10.2–19.0) for second-line treatment groups. Median OS was not reached in the first-line group and was 46.7 months (38.8-not estimated) for the second-line group. The 36-month OS rates for de novo metastasis, treatment-free interval (TFI) ≥ 12 months, and TFI &lt; 12 months were 80.2% (69.1–87.7), 82.0% (70.7–89.3), and 66.0% (57.9–72.9), respectively.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The addition of palbociclib to ET was effective for treating HR+/HER2− ABC in Japanese routine clinical practice.</p>","PeriodicalId":56083,"journal":{"name":"Breast Cancer","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140623807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"French national survey on breast cancer care: caregiver and patient views","authors":"Christine Rousset-Jablonski, Barbara Lortal, Sophie Lantheaume, Laurent Arnould, Hélène Simon, Anne-Sophie Tuszynski, Mélanie Courtier, Soukayna Debbah, Marc Lefrançois, Sita Balbin, Anne-Sophie Kably, Alain Toledano","doi":"10.1007/s12282-024-01576-4","DOIUrl":"https://doi.org/10.1007/s12282-024-01576-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>To improve the quality of care for patients with breast cancer, an analysis of the health-care pathway, considering feedback from both health-care practitioners (HCPs) and patients, is needed.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Between 2020 and 2022, we conducted a survey at French breast cancer centers and analyzed information from questionnaires completed by HCPs and patients. We collected information on center organization, diagnostic processes, treatment decisions and modalities, supportive care, patient advocacy groups, and work issues.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Twenty-three breast cancer centers were included and questionnaires completed by 247 HCPs and 249 patients were analyzed. The centers closely followed the legal French framework for cancer treatments, which includes formal diagnostic announcements, multidisciplinary tumor boards, personalized treatment summaries, and supportive care access. HCPs and patients were satisfied with the time to diagnosis (≤ 2 weeks as evaluated by 75% of patients), time to surgery (mean 61 days), time between surgery and chemotherapy (mean 47 days), and time between surgery and radiotherapy (mean 81 days). Fertility preservation counseling for women under 40 years of age was systematically offered by 67% of the HCPs. The majority (67%) of the patients indicated that they had received a personalized treatment summary; the topics discussed included treatments (92%), tumor characteristics (84%), care pathways (79%), supportive care (52%), and breast reconstruction (33%). Among HCPs, 44% stated that reconstructive surgery was offered to all eligible patients and 57% and 45% indicated coordination between centers and primary care physicians for adverse effects management and access to supportive care should be improved, for chemotherapy and radiotherapy, respectively. Regarding patient advocacy groups, 34% of HCPs did not know whether patients had contact and only 23% of patients declared that they had such contact. For one-third of working patients, work issues were not discussed. Twenty-eight percent of patients claimed that they had faced difficulties for supportive care access. Among HCPs, 13% stated that a formal personalized survivorship treatment program was administered to almost all patients and 37% almost never introduced the program to their patients. Compliance to oral treatments was considered very good for 75–100% of patients by 62% of HCPs.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>This study provides an updated analysis of breast cancer care pathways in France. Overall, the initial processes of diagnosis, announcement, and treatment were swift and were in agreement with the best care standards. No barriers to accessing care were identified. Based on the study findings, we proposed several strategies to improve the quality of care for patients in supportive care, coordination wit","PeriodicalId":56083,"journal":{"name":"Breast Cancer","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140611961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer","authors":"Huan-ping Zhang, Rui-yuan Jiang, Jia-yu Zhu, Ke-na Sun, Yuan Huang, Huan-huan Zhou, Ya-bing Zheng, Xiao-jia Wang","doi":"10.1007/s12282-024-01567-5","DOIUrl":"https://doi.org/10.1007/s12282-024-01567-5","url":null,"abstract":"<p>Triple-negative breast cancer (TNBC) is a highly heterogeneous tumor lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. It has higher aggressiveness and metastasis than other subtypes, with limited effective therapeutic strategies, leading to a poor prognosis. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling pathway is prevalently over-activated in human cancers and contributes to breast cancer (BC) growth, survival, proliferation, and angiogenesis, which could be an interesting therapeutic target. This review summarizes the PI3K/AKT/mTOR signaling pathway activation mechanism in TNBC and discusses the relationship between its activation and various TNBC subtypes. We also report the latest clinical studies on kinase inhibitors related to this pathway for treating TNBC. Our review discusses the issues that need to be addressed in the clinical application of these inhibitors.</p>","PeriodicalId":56083,"journal":{"name":"Breast Cancer","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140612138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The usefulness of artificial intelligence in breast reconstruction: a systematic review","authors":"Karla C. Maita, Francisco R. Avila, Ricardo A. Torres-Guzman, John P. Garcia, Gioacchino D. De Sario Velasquez, Sahar Borna, Sally A. Brown, Clifton R. Haider, Olivia S. Ho, Antonio Jorge Forte","doi":"10.1007/s12282-024-01582-6","DOIUrl":"https://doi.org/10.1007/s12282-024-01582-6","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Artificial Intelligence (AI) offers an approach to predictive modeling. The model learns to determine specific patterns of undesirable outcomes in a dataset. Therefore, a decision-making algorithm can be built based on these patterns to prevent negative results. This systematic review aimed to evaluate the usefulness of AI in breast reconstruction.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A systematic review was conducted in August 2022 following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. MEDLINE, EMBASE, SCOPUS, and Google Scholar online databases were queried to capture all publications studying the use of artificial intelligence in breast reconstruction.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total of 23 studies were full text-screened after removing duplicates, and twelve articles fulfilled our inclusion criteria. The Machine Learning algorithms applied for neuropathic pain, lymphedema diagnosis, microvascular abdominal flap failure, donor site complications associated to muscle sparing Transverse Rectus Abdominis flap, surgical complications, financial toxicity, and patient-reported outcomes after breast surgery demonstrated that AI is a helpful tool to accurately predict patient results. In addition, one study used Computer Vision technology to assist in Deep Inferior Epigastric Perforator Artery detection for flap design, considerably reducing the preoperative time compared to manual identification.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>In breast reconstruction, AI can help the surgeon by optimizing the perioperative patients’ counseling to predict negative outcomes, allowing execution of timely interventions and reducing the postoperative burden, which leads to obtaining the most successful results and improving patient satisfaction.</p>","PeriodicalId":56083,"journal":{"name":"Breast Cancer","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140603261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inter- and intra-observer variability of qualitative visual breast-composition assessment in mammography among Japanese physicians: a first multi-institutional observer performance study in Japan","authors":"Yoichi Koyama, Kazuaki Nakashima, Shunichiro Orihara, Hiroko Tsunoda, Fuyo Kimura, Natsuki Uenaka, Kanako Ban, Yukiko Michishita, Yoshihide Kanemaki, Arisa Kurihara, Kanae Tawaraya, Masataka Taguri, Takashi Ishikawa, Takayoshi Uematsu","doi":"10.1007/s12282-024-01580-8","DOIUrl":"https://doi.org/10.1007/s12282-024-01580-8","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Visual assessment of mammographic breast composition remains the most common worldwide, although subjective variability limits its reproducibility. This study aimed to investigate the inter- and intra-observer variability in qualitative visual assessment of mammographic breast composition through a multi-institutional observer performance study for the first time in Japan.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>This study enrolled 10 Japanese physicians from five different institutions. They used the new Japanese breast-composition classification system 4th edition to subjectively evaluate the breast composition in 200 pairs of right and left normal mediolateral oblique mammograms (number determined using precise sample size calculations) twice, with a 1-month interval (median patient age: 59 years [range 40–69 years]). The primary endpoint of this study was the inter-observer variability using kappa (<i>κ</i>) value.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Inter-observer variability for the four and two classes of breast-composition assessment revealed moderate agreement (Fleiss’ <i>κ</i>: first and second reading = 0.553 and 0.587, respectively) and substantial agreement (Fleiss’ κ: first and second reading = 0.689 and 0.70, respectively). Intra-observer variability for the four and two classes of breast-composition assessment demonstrated substantial agreement (Cohen’s <i>κ</i>, median = 0.758) and almost perfect agreement (Cohen’s <i>κ</i>, median = 0.813). Assessments of consensus between the 10 physicians and the automated software Volpara® revealed slight agreement (Cohen’s <i>κ</i>; first and second reading: 0.104 and 0.075, respectively).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Qualitative visual assessment of mammographic breast composition using the new Japanese classification revealed excellent intra-observer reproducibility. However, persistent inter-observer variability, presenting a challenge in establishing it as the gold standard in Japan.</p>","PeriodicalId":56083,"journal":{"name":"Breast Cancer","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140596892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute adverse events of ultra-hypofractionated whole-breast irradiation after breast-conserving surgery for early breast cancer in Japan: an interim analysis of the multi-institutional phase II UPBEAT study","authors":"Peter J. K. Tokuda, Takamasa Mitsuyoshi, Yuka Ono, Takahiro Kishi, Yoshiharu Negoro, Setsuko Okumura, Itaru Ikeda, Takashi Sakamoto, Yumi Kokubo, Ryo Ashida, Toshiyuki Imagumbai, Mikiko Yamashita, Hiroaki Tanabe, Sayaka Takebe, Mariko Tokiwa, Eiji Suzuki, Chikako Yamauchi, Michio Yoshimura, Takashi Mizowaki, Masaki Kokubo","doi":"10.1007/s12282-024-01577-3","DOIUrl":"https://doi.org/10.1007/s12282-024-01577-3","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>The applicability of ultra-hypofractionated (ultra-HF) whole-breast irradiation (WBI) remains unknown in Japanese women. This study aimed to evaluate the safety and efficacy of this approach among Japanese women and report the results of an interim analysis performed to assess acute adverse events (AEs) and determine whether it was safe to continue this study.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We enrolled Japanese women with invasive breast cancer or ductal carcinoma in situ who had undergone breast-conserving surgery, were aged ≥ 40 years, had pathological stages of Tis–T3 N0–N1, and had negative surgical margins. Ultra-HF-WBI was delivered at 26 Gy in five fractions over one week. When the number of enrolled patients reached 28, patient registration was paused for three months. The endpoint of the interim analysis was the proportion of acute AEs of grade ≥ 2 (Common Terminology Criteria for Adverse Events v5.0) within three months.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Of the 28 patients enrolled from seven institutes, 26 received ultra-HF-WBI, and 2 were excluded due to postoperative infections. No AEs of grade ≥ 3 occurred. One patient (4%) experienced grade 2 radiation dermatitis, and 18 (69%) had grade 1 radiation dermatitis. The other acute grade 1 AEs experienced were skin hyperpigmentation (n = 10, 38%); breast pain (n = 4, 15%); superficial soft tissue fibrosis (n = 3, 12%); and fatigue (n = 1, 4%). No other acute AEs of grade ≥ 2 were detected.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Acute AEs following ultra-HF-WBI were within acceptable limits among Japanese women, indicating that the continuation of the study was appropriate.</p>","PeriodicalId":56083,"journal":{"name":"Breast Cancer","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140596891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases","authors":"Alexandre De Moura, Delphine Loirat, Sarah Vaillant, Sinen Korbi, Nicolas Kiavue, Diana Bello Roufai, Laurence Escalup, Romain Desmaris, Pauline Vaflard, Paul Cottu, Jean-Yves Pierga, François-Clément Bidard, Luc Cabel, Alexandre Acramel","doi":"10.1007/s12282-024-01565-7","DOIUrl":"https://doi.org/10.1007/s12282-024-01565-7","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Sacituzumab govitecan (SG) has been approved by FDA in April 2021 for pre-treated metastatic triple-negative breast cancer (mTNBC), following the ASCENT trial results.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We set up an ambispective bicentric cohort study to assess the real-world effectiveness and safety of SG in patients with mTNBC treated at Institut Curie Hospitals, with a focus on patients with brain metastases.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>This study included 99 patients treated through the French Early Access Program to SG from May 2021 to January 2023. Median age was 55 years [26–89], <i>N</i> = 8 patients (8%) had <i>BRCA1/2</i> mutation, <i>N</i> = 12 (12%) de novo stage IV disease and <i>N</i> = 31 (31%) brain metastases. Patients had previously received a median of two [1–10] lines of treatment in advanced setting. After a median follow-up of 9.7 months, the median progression-free survival (PFS) and overall survival (OS) were 3.9 months (95%CI[3.4–5.0]) and 8.6 months (95%CI[7.1–11.9]), respectively, while objective response rate was 29% (95%CI[21–39]). Among patients with brain metastases, median PFS and OS were 3.7 months (95%CI[2.6–6.2]) and 6.7 months (95%CI[6.3–NR]), respectively, with intracranial tumor responses. Dose reductions were required in <i>N</i> = 17 patients (17%) within a median of three [2–11] cycles, due to gastrointestinal toxicity (<i>N</i> = 6; 6%), hematological toxicity (<i>N</i> = 9; 9%) including febrile neutropenia (<i>N</i> = 2; 2%), liver enzyme elevation (<i>N</i> = 1; 1%), and physical deterioration (<i>N</i> = 1; 1%). There was no related death to SG.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>The observed response rate and safety of SG are consistent with the results of the ASCENT trial, with efficacy observed in patients with brain metastases, but observed PFS and OS are numerically shorter.</p>","PeriodicalId":56083,"journal":{"name":"Breast Cancer","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140596934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between quality of life and mortality risk in patients with breast cancer: a systematic review and meta-analysis","authors":"Katsuyoshi Suzuki, Shinichiro Morishita, Jiro Nakano, Taro Okayama, Junichiro Inoue, Takashi Tanaka, Takuya Fukushima","doi":"10.1007/s12282-024-01581-7","DOIUrl":"https://doi.org/10.1007/s12282-024-01581-7","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Patients with breast cancer present with various problems that have an adverse effect on the quality of life (QOL). However, the association between the QOL and mortality among patients with breast cancer remains controversial. Therefore, this systematic review and meta-analysis aimed to determine whether QOL impacts prognosis in patients with breast cancer.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The databases of CINAHL, Scopus, and PubMed databases were searched to retrieve observational studies that assessed the QOL and mortality risk in patients with breast cancer published before December 2022.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Among the 119,061 articles retrieved, six observational studies were included in the meta-analysis. Physical QOL (hazard ratio [HR]: 1.04, 95% confidence interval [CI]: 1.01–1.07, p = 0.003), emotional QOL (HR: 1.01, 95% CI: 1.00–1.03, p = 0.05), and role QOL (HR: 1.01, 95% CI: 1.00–1.01, p = 0.007) showed significant associations with mortality risk. In contrast, global QOL, cognitive QOL, and social QOL showed no associations with mortality risk. Subgroup analysis performed according to treatment time points revealed that the post-treatment physical QOL was associated with mortality risk.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Physical QOL, emotional QOL, and role QOL are associated with mortality risk in patients with breast cancer. Furthermore, post-treatment physical QOL showed a more significant association with prolonged survival than pre-treatment physical QOL.</p>","PeriodicalId":56083,"journal":{"name":"Breast Cancer","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140596933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nipple–areolar complex malposition in breast reconstruction after nipple-sparing mastectomy: a multi-institutional retrospective observational study in Japan","authors":"Sayuri Kato, Hiroki Mori, Miho Saiga, Satoko Watanabe, Shinsuke Sasada, Ayano Sasaki, Akiko Ogiya, Mao Yamamoto, Kazutaka Narui, Junji Takano, Hirohito Seki, Naomi Nagura, Makoto Ishitobi, Tadahiko Shien","doi":"10.1007/s12282-024-01578-2","DOIUrl":"https://doi.org/10.1007/s12282-024-01578-2","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Position of the nipple–areolar complex (NAC) is an important factor in the esthetic impression of the breast, and NAC malposition is often an issue in breast reconstruction after nipple-sparing mastectomy (NSM). The purpose of this study was to evaluate the degree of NAC malposition depending on several factors using data quantified with the Mamma Balance application (Medic Engineering K.K., Kyoto, Japan).</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Patients who underwent unilateral breast reconstruction after NSM at eight hospitals in Japan between 2007 and 2020 were retrospectively investigated. Using Mamma Balance, NAC malposition was quantified separately in horizontal and vertical directions using patient photographs from pre-operatively and 6–24 months post-operatively. The degree of malpositioning was then statistically compared using various factors.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The NAC deviated more cranially and medially with implants than that with flaps. Cases with latissimus dorsi flap showed lateral malposition more often than cases with deep inferior epigastric artery perforator flap. With flaps, lateral incisions showed more lateral malposition, and peri-areolar incisions tended to show more medial NAC malposition. In cases with severe post-operative infection of the implant, the NAC tended to deviate cranially. In radiation cases, the NAC deviated cranially. No significant difference was observed according to the degree of breast ptosis or use of the pull-down operation. Only a very weak correlation was observed between a larger amount of mastectomy and more cranial NAC malposition with both flaps and implants.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>This study provides insights into the tendencies and characteristics of NAC malposition.</p>","PeriodicalId":56083,"journal":{"name":"Breast Cancer","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140596861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}